This is the first part of our interview with the esteemed Professor Thomas Borody, which covers the following aspects:
- What is the recommended ivermectin-based tri-therapy
- How is this early therapy administered to old and younger people alike
- Examples of elderly people “turning the corner” after being treated
- The increasing adoption of the tri-therapy in Australia
Professor Thomas Borody is a world renowned medical doctor from Australia with over 40 years experience in clinical research and practice, including at the St Vincent Hospital in Sydney and at the Mayo clinic in the US.
Some of his most ground breaking contributions in medical science include the development of a tritherapy for peptic ulcers, the development of faecal microbiota transplants for colitis and other diseases, and recently, a therapy for Crohn disease.
In 1984 he established the Centre for Digestive Diseases in Sydney. He oversaw its growth into an active clinical research institute with 65 employees.
Professor Borody has published numerous articles and is a reviewer for leading international medical journals.
With the pandemic, Professor Borody took a particular interest in researching a therapy for COVID-19, and this is what this interview is all about.
See our previous articles: